Parkinson's disease: etiopathogenesis and treatment

J Jankovic, EK Tan - Journal of Neurology, Neurosurgery & Psychiatry, 2020 - jnnp.bmj.com
The concept of 'idiopathic'Parkinson's disease (PD) as a single entity has been challenged
with the identification of several clinical subtypes, pathogenic genes and putative causative …

Exosomes based strategies for brain drug delivery

FU Rehman, Y Liu, M Zheng, B Shi - Biomaterials, 2023 - Elsevier
Exosome application has emerged as a promising nanotechnology discipline for various
diseases therapeutics and diagnoses. Owing to the natural properties of efficient drug …

[PDF][PDF] Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01

J Piao, S Zabierowski, BN Dubose, EJ Hill, M Navare… - Cell stem cell, 2021 - cell.com
Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia
nigra leading to disabling deficits. Dopamine neuron grafts may provide a significant …

Engineering of magnetic nanoparticles as magnetic particle imaging tracers

C Lu, L Han, J Wang, J Wan, G Song… - Chemical Society Reviews, 2021 - pubs.rsc.org
Magnetic particle imaging (MPI) has recently emerged as a promising non-invasive imaging
technique because of its signal linearly propotional to the tracer mass, ability to generate …

[PDF][PDF] Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use

TW Kim, J Piao, SY Koo, S Kriks, SY Chung, D Betel… - Cell stem cell, 2021 - cell.com
Human pluripotent stem cells show considerable promise for applications in regenerative
medicine, including the development of cell replacement paradigms for the treatment of …

Co-transplantation of autologous Treg cells in a cell therapy for Parkinson's disease

TY Park, J Jeon, N Lee, J Kim, B Song, JH Kim, SK Lee… - Nature, 2023 - nature.com
The specific loss of midbrain dopamine neurons (mDANs) causes major motor dysfunction
in Parkinson's disease, which makes cell replacement a promising therapeutic approach …

Alpha-Synuclein aggregation pathway in Parkinson's disease: current status and novel therapeutic approaches

M Vidović, MG Rikalovic - Cells, 2022 - mdpi.com
Following Alzheimer's, Parkinson's disease (PD) is the second-most common
neurodegenerative disorder, sharing an unclear pathophysiology, a multifactorial profile …

Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons

TS Pearson, N Gupta, W San Sebastian… - Nature …, 2021 - nature.com
Aromatic L-amino acid decarboxylase (AADC) deficiency is a rare genetic disorder
characterized by deficient synthesis of dopamine and serotonin. It presents in early infancy …

Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors

E Ghasempour, S Hesami, E Movahed… - Stem Cell Research & …, 2022 - Springer
Brain tumors are one of the most mortal cancers, leading to many deaths among kids and
adults. Surgery, chemotherapy, and radiotherapy are available options for brain tumor …

In vitro modeling of the human dopaminergic system using spatially arranged ventral midbrain–striatum–cortex assembloids

D Reumann, C Krauditsch, M Novatchkova, E Sozzi… - Nature …, 2023 - nature.com
Ventral midbrain dopaminergic neurons project to the striatum as well as the cortex and are
involved in movement control and reward-related cognition. In Parkinson's disease …